Sentences with phrase «medicine company with»

SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced two presentations at ISSCR 2016 Annual Meeting.

SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.

San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product candidate.

SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.

SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.

SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.

SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.

3DS is a personalized medicine company with a software platform based on the three - dimensional analysis of chromosomal signatures.

Not exact matches

So many companies have developed such increasingly effective medicines, such as those that treat more hep C strains with far shorter treatment regimens, that Gilead — a pioneer in the field with Sovaldi and Harvoni — is projecting $ 3.5 billion to $ 4 billion in U.S. sales from these kinds of drugs in 2018, a dramatic drop from nearly $ 13 billion in 2015.

UPDATE: Editas Medicine co-founder Jennifer Doudna left the company in 2014, after just seven months, and has had no additional involvement with the company, according to the company's S - 1 filing.

Cook met with USA TODAY to discuss the company's expanded corporate partnership with (RED), the 20 - person organization founded by U2 singer Bono that has had an outsized impact on those suffering from HIV / AIDS by providing life - saving medicines.

Recent research published in the Journal of Occupational and Environmental Medicine found the performance of workers with insomnia or sleep problems lags their well - rested colleagues, and that costs companies between $ 2,500 and $ 3,156 annually per sleepy employee.

He's credited with pursuing a litigation strategy over the company's Vioxx pain relief medicine that saved the company between $ 15 billion and $ 45 billion against what analysts had predicted it would cost.

The memory - eating disease, expected to afflict 15 million Americans by 2060 (and tens of millions more around the world as life expectancy increases), has no cure; a new drug for the condition hasn't been approved in well over a decade; initially promising experimental treatments seem to be failing with clockwork regularity; and there's not even a definitive consensus on what, exactly, biopharma companies should focus on while developing Alzheimer's medicines.

You have that coinciding with media stories of companies that have maybe taken advantage of what the U.S. system offers, which is the freedom to price and market your medicines how you want, in a very negative way.

Consider: the arsenal of effective (and less risky) HIV medicines has ballooned, the stigma associated with the disease has declined (although, as activists note, much work remains to be done on that front), and awareness campaigns centered on HIV / AIDS have gone from what was a fringe movement just 30 years ago to a cause championed by top public figures and companies around the world.

A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring these medicines to patients globally.

CNBC's Meg Tirrell speaks with Verily Chief Medical Officer Dr. Jessica Mega about the role Alphabet plays in the biotech company and what it could mean for the future of medicine.

As the incidents of chronic illness continue to skyrocket, and as the public becomes increasingly frustrated with the limitations of conventional medicine in response, companies across America are taking matters into their own hands.

«The use of the medicines in lethal injections runs counter to the manufacturers» mission to save and enhance patients» lives, and carries with it not only a public - health risk, but also reputational, fiscal and legal risks,» wrote the companies in a friend of the court filing.

In an exclusive interview, Ms. Holmes talks to Medscape Editor - in - Chief Eric J. Topol, MD, about the decade she spent building her company; plans for the present and the future, including a recent deal with Walgreens drugstores; and whether she's on the path to the creative destruction of laboratory medicine.

It is a fascinating story about a very influential company that has relationships with some of the biggest names in healthcare, including: Oakland, Calif. - based Kaiser Permanente, Cleveland Clinic, Johns Hopkins Medicine in Baltimore, UCLA Health in Los Angeles, Arlington - based Texas Health Resources, Massachusetts General Hospital in Boston, Mount Sinai Health System in New York City and Duke University Health System in Raleigh, N.C.

The California Medical Association, which represents doctors in California, opposes the measure because of that claim, and also because the group said the cancellation of drug purchasing contracts the state already has with pharma companies «would remove many drugs from the Medi - Cal list of pre-approved medicines — creating a new prior authorization hurdle for patients and their physicians.»

The combined company will benefit from a broader innovative portfolio of leading medicines in key categories and a platform for sustainable growth with diversified payer groups.

The takeover interest in Tesaro underscores the pharmaceutical industry's strong appetite for the acquisition of biotechnology companies with promising medicines under development in lucrative sectors such as cancer treatment.

Corridor - based companies are engineering next - generation electronics and nanoparticles with broad applications in computing, energy and even medicine.

100 % foreign ownership allowed Cold storage Sports centers Film processing labs Rubber and sugar industry) when engaging in partnerships with local farmers and use 30 % domestically produced raw material) Warehousing Tourism, E-commerce (with a marketplace value above 10 billion rupiahs and when working with local warehousing companies) Toll road operators Telecom device certification Non-hazardous waste management Raw medicine materials Pharmaceutical ventures Restaurants, bars, cafés Film making Film distribution Cinemas (required to show Indonesian films at least 60 per cent of their screen time) Direct selling Futures trading

Walter A. De Brouwer Ph.D., is the founder and CEO of doc.ai, an AI company with a presence on the Blockchain that uses Machine Learning on Precision Medicine.

Drug companies often face the need to come up with new medicines, especially as patents on older pharmaceuticals expire.

In a statement, it wrote that «any allegations of disregard for consumers who need these lifesaving drugs, government officials, regulators or any other of our valued stakeholders are patently false and wholly inconsistent with the company's culture, mission and track record of delivering access to medicine.»

The clinical - stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life - altering central nervous system (CNS) disorders, SAGE Therapeutics Inc. (NASDAQ: SAGE) seem to be poised for a price surge as per its latest charts.

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

Last month, representatives from the California - based social networking company were negotiating a data - sharing agreement with health organizations such as the American College of Cardiology and the Stanford University School of Medicine in California.

Some Pioneer AAs did read the following titles which mention a «higher power» of one sort or another: (1) Ralph Waldo Trine, In Tune with the Infinite: Or Fullness of Peace, Power, and Plenty (NY: Thomas H. Crowell, 1897); (2) William James, The Varieties of Religious Experience (NY: First Vintage Press / The Library of America Edition, 1990); (3) Elwood Worcester, Samuel McComb, and Isador H. Coriat, Religion and Medicine: The Moral Control of Nervous Disorders (NY: Moffat, Yard & Company, 1908); (4) Victor C. Kitchen, I Was a Pagan (NY: Harper & Brothers, 1934); (5) A. J. Russell, For Sinners Only (London: Hodder & Stoughton, 1932).

Filed Under: Cancer, Chemotherapy Recipes, Cooking For Cancer, Desserts and Cookies, gluten - free, healthy choices, smoothies, Special Diets, vegetarian Tagged With: cancer, food as medicine, food during chemotherapy, food for mouthsores, HopeFULL Company, kids channel, kids cooking, kids in the kitchen, kids video, popsicles

Ruike and her colleagues have filed a patent on their technique and are continuing to collaborate with the medical supply company, which is currently making plans to manufacture medicine patches made from kirigami films.

Five years later, Gilead became the first pharmaceutical company to sign an agreement with the newly formed Medicines Patent Pool — an organisation formed to coordinate the licensing of patent - protected medicines so that they can be produced in generic form for low income countries.

Researchers from the Singapore - MIT Alliance for Research and Technology (SMART), DukeNUS Graduate School of Medicine (Duke - NUS), National University of Singapore (NUS) and Nanyang Technological University (NTU) have collaborated with the Massachusetts Institute of Technology (MIT) and a biotechnology company, Visterra, to develop a single treatment.

Food & beverage companies spend $ 2 billion a year on youth - targeted ads, with American children seeing approximately 4,700 ads each year and teens viewing 5,900 ads per year, according to Institute of Medicine research.

For aspiring geneticists, the lesson of the two companies» transformations is that genetics is moving into the realm of the practical, with the promise of personalized medicine and pharmacogenomics.

«Young companies trying to get into pharmacogenomics and personalized medicine are facing daunting challenges because of uncertainties with FDA and just the inherent difficulties of trying to change the paradigm to something where side effects are unacceptable,» says Galas.

«Personalized medicine companies [have been] trying to deal with this for going on 2 years and keep expressing a lot of frustration,» Sauer says.

Last year, it came to light that Merck had paid the publishing company Elsevier to produce a journal, Australasian Journal of Bone & Joint Medicine, which looked like a peer - reviewed medical journal but was filled with articles and reviews from MECs, including articles favorable to Merck products for osteoporosis.

Kazuyoshi Maejima of the School of Medicine at Keio University in Tokyo led a team of academics that developed the Koken rat jointly with company researchers.

«This is about the same difference between hearing with your hands over your ears, and what you hear ordinarily,» says Lloyd Klickstein, head of translational medicine at Novartis, the Swiss drug company collaborating on the trial.

Novartis is one of many drug companies with new medicines being tested in humans, according to Pharmaceutical Research and Manufacturers of America.

A Web - based app for physicians called Modernizing Medicine crunches data sets to recommend disease treatments and RealDoll, a company that produces sex dolls, is experimenting with AI features to make their products more responsive.

In Texas the Ebola patient is now stable but in critical condition and being treated with brincidofovir, an oral medicine developed by Durham, N.C. — based biopharmaceutical company, Chimerix.

But Marcia Angell, a senior lecturer in social medicine at Harvard Medical School and the former editor of The New England Journal of Medicine, says companies often structure research in a manner that is most likely to yield favorable conclusions — by comparing a medication against a placebo, for instance, instead of comparing it with its most effective compmedicine at Harvard Medical School and the former editor of The New England Journal of Medicine, says companies often structure research in a manner that is most likely to yield favorable conclusions — by comparing a medication against a placebo, for instance, instead of comparing it with its most effective compMedicine, says companies often structure research in a manner that is most likely to yield favorable conclusions — by comparing a medication against a placebo, for instance, instead of comparing it with its most effective competitors.